Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product administration interrupted, Product availability issue
Clinical narrative: received her first dose of the Moderna Covid-19 vaccine on March 11, 2023 / now having trouble finding her second dose of the Moderna Covid-19 primary series/ More than 35 days in between her primary series Moderna Covid-19 vaccines; The patient is now having trouble finding her second dose of the Moderna Covid-19 primary series; No adverse event; This spontaneous case was reported by a patient and describes the occurrence of PRODUCT ADMINISTRATION INTERRUPTED (received her first dose of the Moderna Covid-19 vaccine on March 11, 2023 / now having trouble finding her second dose of the Moderna Covid-19 primary series/ More than 35 days in between her primary series Moderna Covid-19 vaccines), PRODUCT AVAILABILITY ISSUE (The patient is now having trouble finding her second dose of the Moderna Covid-19 primary series) and NO ADVERSE EVENT (No adverse event) in an adult female patient who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     No Medical History information was reported.    On 11-Mar-2023, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTRATION INTERRUPTED (received her first dose of the Moderna Covid-19 vaccine on March 11, 2023 / now having trouble finding her second dose of the Moderna Covid-19 primary series/ More than 35 days in between her primary series Moderna Covid-19 vaccines), PRODUCT AVAILABILITY ISSUE (The patient is now having trouble finding her second dose of the Moderna Covid-19 primary series) and NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT ADMINISTRATION INTERRUPTED (received her first dose of the Moderna Covid-19 vaccine on March 11, 2023 / now having trouble finding her second dose of the Moderna Covid-19 primary series/ More than 35 days in between her primary series Moderna Covid-19 vaccines), PRODUCT AVAILABILITY ISSUE (The patient is now having trouble finding her second dose of the Moderna Covid-19 primary series) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for PRODUCT ADMINISTRATION INTERRUPTED (received her first dose of the Moderna Covid-19 vaccine on March 11, 2023 / now having trouble finding her second dose of the Moderna Covid-19 primary series/ More than 35 days in between her primary series Moderna Covid-19 vaccines) and PRODUCT AVAILABILITY ISSUE (The patient is now having trouble finding her second dose of the Moderna Covid-19 primary series).    Concomitant medication details not reported by the reporter. Patient received her first dose of the Moderna Covid-19 vaccine on March 11, 2023 at a Pharmacy. The patient is now having trouble finding her second dose of the Moderna Covid-19 primary series. More than 35 days in between her primary series Moderna Covid-19 vaccines. The patient did not want to provide any additional information.  Treatment details was not reported by the reporter.   Reporter did not allow further contact